Cresaryn builds on the wider NanoCelle delivery platform, which has been developed over approximately eight years with substantial historical research and development investment. Existing company materials describe extensive platform manufacturing and administration experience across other NanoCelle applications. This background supports formulation knowledge and delivery-system familiarity.
Product-specific research has focused on selecting and characterising a lead oro-buccal tadalafil formulation, developing analytical and bioanalytical methods, planning stability and manufacturing activities and defining the evidence needed to test earlier-exposure potential. In-vitro work is intended to establish formulation properties, product quality and method performance. Preclinical pharmacokinetic work is planned to assess exposure, while the 30-day minipig program is designed to evaluate local oral and buccal tolerance and systemic safety.
The scientific rationale combines an established active ingredient with an alternative delivery approach. Tadalafil’s PDE5 mechanism and long-duration profile are well characterised. Cresaryn is intended to alter how the active is presented and absorbed, using a metered spray and an opportunity for buccal uptake. It does not change tadalafil’s pharmacological target.
Cresaryn is developing its tadalafil oro-buccal spray through a proposed United States 505(b)(2) pathway. This route may permit an application to rely partly on FDA findings or published information relating to an already approved active ingredient, while providing new evidence needed for the NanoCelle formulation, route, device and proposed product claims. The final regulatory strategy, reference product, required studies and submission content remain subject to FDA agreement.